Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Sinovac Announces Much Lower First Quarter

publication date: May 15, 2009
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

Sinovac Biotech (北京科兴生物制品有限公司) reported a substantial 26% decline in Q1 sales, which fell from $8.9 million in 2008 to only $6.6 million this year. The revenue drop left net income at a barely positive level of just $25,000, down from $1.6 million in last year’s first quarter. Nevertheless, despite the weakening in its revenue trend, Sinovac courageously called for full-year 2009 revenues of $55-$60 million, a 20% increase. It’s a long way from a $6.6 million first quarter to a $60 million year. More details...

Stock Symbol: (NYSE Amex: SVA)




Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors